60 reports

It is indicated for the prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving a kidney transplant and liver transplant.

  • Cancer
  • Lung Cancer
  • Therapy
  • United States
  • Product Initiative
  • Clinical Trial profile. 321 Trial Title
  • Clinical Trial profile. 142 Trial Title

Clinical Trial profile. ## Trial Title Official Title Trial Identifier Secondary ID(s) Therapy Area Indication(s) Trial Status Trial Phase Study Type Drug(s)/ Molecule(s) Sponsor(s) Estimated Start Date Actual Start date Estimated Completion Date # of Subjects Planned # of Location(s) #

  • Clinical Trial
  • Hepatitis
  • Lung Cancer
  • Therapy
  • World
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H1 2019
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2019

THE DRUG CANDIDATE IS IN PHASE II STAGE OF DEVELOPMENT FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS, NONALCOHOLIC FATTY LIVER DISEASE, HCV RECURRENCE POST TRANSPLANT, RENAL IMPAIREMENT, AUTOIMMUNE HEPATITIS, PORTAL HYPERTENSION, ACUTE-ONCHRONIC LIVER FAILURE,

  • Chemotherapy
  • Digestive System Disorder
  • Lung Cancer
  • Therapy
  • Conatus Pharmaceuticals Inc.

It is indicated for the prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving a kidney transplant and liver transplant.

  • Cancer
  • Lung Cancer
  • United States
  • Product Initiative
  • Merck & Co., Inc.

IT IS INDICATED FOR THE PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A KIDNEY TRANSPLANT AND LIVER TRANSPLANT.

  • Hospital
  • Lung Cancer
  • Therapy
  • United States
  • Merck & Co., Inc.
  • PIPELINE BY BEYONDSPRING INC, H2 2018
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2018

THE DRUG CANDIDATE IS IN PHASE II STAGE OF DEVELOPMENT FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS, NONALCOHOLIC FATTY LIVER DISEASE, HCV RECURRENCE POST TRANSPLANT, RENAL IMPAIRMENT, AUTOIMMUNE HEPATITIS, PORTAL HYPERTENSION, ACUTE-ONCHRONIC LIVER FAILURE,

  • Digestive System Disorder
  • Lung Cancer
  • World
  • Product Initiative
  • Conatus Pharmaceuticals Inc.
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H1 2018
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018

The POLT-HCV-SVR trial, initiated in the second quarter of 2014, enrolled post-orthotopic liver transplant (POLT) recipients whose transplanted livers were damaged by recurrent HCV infection.

  • Digestive System Disorder
  • Lung Cancer
  • United States
  • World
  • Product Initiative

The prominent features of this report are - ##.

  • Lung Cancer
  • Medical Biotechnology
  • Therapy
  • World
  • Product Initiative
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018
  • GLOBAL MARKETS DIRECT REPORT COVERAGE

THE DRUG CANDIDATE IS IN PHASE II STAGE OF DEVELOPMENT FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS, NONALCOHOLIC FATTY LIVER DISEASE, HCV RECURRENCE POST TRANSPLANT, RENAL IMPAIRMENT, AUTOIMMUNE HEPATITIS, PORTAL HYPERTENSION, ACUTE-ONCHRONIC LIVER FAILURE,

  • Chemotherapy
  • Lung Cancer
  • United States
  • World
  • Product Initiative
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2018

The POLT-HCV-SVR trial, initiated in the second quarter of 2014, enrolled post-orthotopic liver transplant (POLT) recipients whose transplanted livers were damaged by recurrent HCV infection.

  • Chemotherapy
  • Digestive System Disorder
  • Lung Cancer
  • United States
  • Product Initiative
  • Research and Development Brief

It is indicated for the prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving a kidney transplant and liver transplant.

  • Lung Cancer
  • Therapy
  • United States
  • Product Initiative
  • Bristol-Myers Squibb Company

The prominent features of this report are - ##.

  • Clinical Trial
  • Lung Cancer
  • Monoclonal Antibody
  • World
  • Product Initiative

It is indicated for the prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving a kidney transplant and liver transplant.

  • Lung Cancer
  • Therapy
  • United States
  • Product Initiative
  • Merck & Co., Inc.

It is indicated for the prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving a kidney transplant and liver transplant.

  • Lung Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Merck & Co., Inc.
  • Research and Development Brief

It is indicated for the prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving a kidney transplant and liver transplant.

  • Cancer
  • Lung Cancer
  • Pharmaceutical
  • Therapy
  • Merck & Co., Inc.
  • Research and Development Brief

IT IS INDICATED FOR THE PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A KIDNEY TRANSPLANT AND LIVER TRANSPLANT.

  • Cancer
  • Lung Cancer
  • North America
  • United States
  • Merck & Co., Inc.

In October 2007, Novartis registered a Phase I, an open-label, two-period, multi-center, single dose study to assess the pharmacokinetics of AEB## in de novo liver transplant patients.

  • Lung Cancer
  • Targeted Therapy
  • Therapy
  • United States
  • Product Initiative
  • Research and Development Brief

IT IS INDICATED FOR THE PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A KIDNEY TRANSPLANT AND LIVER TRANSPLANT.

  • Hospital
  • Lung Cancer
  • Targeted Therapy
  • Therapy
  • Bristol-Myers Squibb Company

IT IS INDICATED FOR THE PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A KIDNEY TRANSPLANT AND LIVER TRANSPLANT.

  • Cancer
  • Lung Cancer
  • United States
  • Product Initiative
  • Eisai Co., Ltd.

IT IS INDICATED FOR THE PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A KIDNEY TRANSPLANT AND LIVER TRANSPLANT.

  • Cancer
  • Hospital
  • Lung Cancer
  • Therapy
  • Merck & Co., Inc.
  • 5. All the trials included are unique trials.

An Open Labelled Randomized Everolimus Vs Calcineurin Inhibitors Multicenter Trial (CERTICOEUR) A Secondary Prevention Study of Skin Cancers in Heart Transplant Patients.

  • Clinical Trial
  • Lung Cancer
  • Monoclonal Antibody
  • World
  • Product Initiative
  • Research and Development Brief

IT IS INDICATED FOR THE PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A KIDNEY TRANSPLANT AND LIVER TRANSPLANT.

  • Hospital
  • Lung Cancer
  • Therapy
  • United States
  • Product Initiative

IT IS INDICATED FOR THE PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A KIDNEY TRANSPLANT AND LIVER TRANSPLANT.

  • Lung Cancer
  • Monoclonal Antibody
  • Therapy
  • United States
  • Product Initiative

IT IS INDICATED FOR THE PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A KIDNEY TRANSPLANT AND LIVER TRANSPLANT.

  • Cell Therapy
  • Hospital
  • Lung Cancer
  • Therapy
  • Bristol-Myers Squibb Company

THE STUDY WILL TEST TWO DIFFERENT DOSES OF THE DRUG TO BE SAFER IN PEOPLE NEEDING A LIVER TRANSPLANT AND THE DOSE CHOSEN WILL BE USED IN FURTHER STUDIES TO TEST ART-## TO REDUCE THE CHANCES OF EARLY ALLOGRAFT DYSFUNCTION OCCURRING IN PATIENTS WHO HAVE A LIVER

  • Blood Disease
  • Cell Therapy
  • Lung Cancer
  • Therapy
  • Bristol-Myers Squibb Company

IT IS INDICATED FOR THE PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A KIDNEY TRANSPLANT AND LIVER TRANSPLANT.

  • Hospital
  • Lung Cancer
  • Pharmaceutical
  • Therapy
  • Bristol-Myers Squibb Company

IT IS INDICATED FOR THE PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A KIDNEY TRANSPLANT AND LIVER TRANSPLANT.

  • Lung Cancer
  • Therapy
  • United States
  • Product Initiative
  • Merck & Co., Inc.

THE STUDY WILL TEST TWO DIFFERENT DOSES OF THE DRUG TO BE SAFER IN PEOPLE NEEDING A LIVER TRANSPLANT AND THE DOSE CHOSEN WILL BE USED IN FURTHER STUDIES TO TEST ART-## TO REDUCE THE CHANCES OF EARLY ALLOGRAFT DYSFUNCTION OCCURRING IN PATIENTS WHO HAVE A LIVER

  • Blood Disease
  • Cell Therapy
  • Lung Cancer
  • Therapy
  • Bristol-Myers Squibb Company

IT IS INDICATED FOR THE PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A KIDNEY TRANSPLANT AND LIVER TRANSPLANT.

  • Cancer
  • Hospital
  • Lung Cancer
  • Therapy
  • Bristol-Myers Squibb Company

Liver Congress 2017 PCI Biotech, a clinical-stage company developing innovative therapeutics that address significant unmet medical needs, announced that a poster of the fimaCHEM technology will be presented at the International Liver Congress 2017 - the annual meeting of the Europ

  • Clinical Trial
  • Drug Development
  • Lung Cancer
  • World
  • Eli Lilly & Co.